About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The work of the Biomedical Research in Cancer Stem Cell group focuses mainly on senescence (replicative or stress-induced oncoge). In our laboratory, we carry out several genetic screens based on the detection of new genes / small interfering RNA (siRNA) / microRNAs related to cell proliferation, which have a role in cancer. Therefore, we use different cell models: murine cells, human primary cells or immortalized cells capable of entering senescence.
The objectives of the group are:
A partir de datos preliminares de arrays, hemos caracterizado algunos microRNAs/mRNAs relevantes en tumores. Actualmente los estamos analizando a nivel de pacientes con cáncer en sangre como posible método predictivo antes de la aparición del tumor.
IP: Matilde Lleonart Pajarin
En nuestro laboratorio hemos efectuado diversos “screenings” genéticos para detectar nuevos genes implicados en proliferación celular in vitro que además poséan un papel relevante en cáncer humano. De entre ellos descubrimos la proteínas CIRP, la cual hemos descrito como proteína oncogénica. Actualmente estamos valorando la función de CIRP en diversos tipos tumorales en correlación con la evolución clínica de los pacientes.
Different studies suggest the association between gastroesophageal reflux disease (GERD) and OSAS, but GERD prevalence in OSAS and the severity influence of OSAS upon GERD are not known yet.
OBJECTIVES:
The main objective of this study is to determine the prevalence of GERD in patients with obstructive sleep apnea syndrome using conventional polygraphic sleep. Wiht this study we also want to assess the efficacy of a symptom questionnaire in the diagnosis of gastroesophageal reflux in these patients.
PURPOSE:
Identifying patients with gastroesophageal reflux among patients affected by obstructive sleep apnea, in order to establish therapeutic measures to prevent GERD complications.
IP: Juan Lorente Guerrero, Juan Luis Quesada Martínez, María Jose Jurado Luque
En base a arrays de microRNAs y mRNAs efectuados a partir de tumores humanos, identificamos los más desregulados entre tejidos normales y tumorales para caracterizarlos a nivel molecular.
IP: Matilde Lleonart Pajarin Collaborators: - Funding agency: Fundación hna Funding: 50000 Reference: FUND.HNA/PREMI/LLEONART/2025 Duration: 01/10/2025 - 30/09/2027
IP: Matilde Lleonart Pajarin Collaborators: David Virós Porcuna Funding agency: Ajuntament Barcelona Funding: 2980 Reference: 102034195-25 Duration: 01/09/2025 - 30/06/2026
IP: Matilde Lleonart Pajarin Collaborators: Katerin Ingrid Rojas Laimito, Irene Braña Garcia, David Virós Porcuna, Josep Castellví Vives, Marina Bataller Fernández, Juan Fernando Fuentes Cabrera, Juan Fernando Fuentes Cabrera Funding agency: Instituto de Salud Carlos III Funding: 318750 Reference: AC24/00057 Duration: 01/01/2025 - 31/12/2027
IP: Matilde Lleonart Pajarin Collaborators: Katerin Ingrid Rojas Laimito, Yoelsis Garcia Mayea, Juan Lorente Guerrero, Sergio Benavente Norza, Josep Castellví Vives, Marina Bataller Fernández, Pablo Sanchez Sancho, Juan Fernando Fuentes Cabrera, Juan Fernando Fuentes Cabrera Funding agency: Instituto de Salud Carlos III Funding: 240000 Reference: PI24/00630 Duration: 01/01/2025 - 31/12/2027
PhD student: Almudena Sanchez Garcia, Almudena Sanchez Garcia Director/s: Matilde Lleonart Pajarin, Yoelsis Garcia Mayea University: Universitat Autònoma de Barcelona Year: 2024
PhD student: Angela maria Bellmunt Fontanet Director/s: Juan Lorente Guerrero University: Universidad Autònoma de Barcelona Year: 2018
PhD student: Andrea F Feliciano Aguirre Director/s: Matilde Lleonart Pajarin University: Universidad Autònoma de Barcelona Year: 2017
PhD student: Maja Narlik , Maja Narlik Director/s: Amancio Carnero Moya University: Universidad Autònoma de Barcelona Year: 2012
PhD student: Irene Ferrer , Irene Ferrer Director/s: Amancio Carnero Moya University: Universidad Autònoma de Barcelona Year: 2009
PhD student: María Victoria Moneo , María Victoria Moneo Director/s: Amancio Carnero Moya University: Universidad Autònoma de Barcelona Year: 2009
Experts addressed the main current and future challenges to improve therapeutic options for patients with this type of tumor.
The sessions were aimed at establishing new collaborations to advance the prevention and treatment of this type of tumour.
On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.
